Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives.

Although dose escalation protocols have improved biochemical control in prostate cancer radiotherapy, 10-45% of patients will experience disease recurrence. The prostate and seminal vesicles are the most frequent site of the first relapse. Traditionally, these patients have been managed with hormonal therapy, which is not curative.

Comparison between postoperative TRUS-CT fusion with MRI-CT fusion for postimplant quality assurance in prostate LDR permanent seed brachytherapy.

PURPOSE/OBJECTIVE Permanent seed Low-Dose-Rate brachytherapy is planned and delivered using transrectal ultrasound (TRUS). Post-implant evaluation for quality assurance is usually performed using Computed Tomography (CT). Registration of the CT images with MRI reduces subjectivity in contouring by improving prostate edge detection.

High-dose-rate brachytherapy for localized penile cancer: Evolution of a technique.

Purpose: High-dose-rate (HDR) brachytherapy is a convenient treatment option for selected patients with T1-T2 penile squamous cell carcinoma (SCC), providing high rates of penile preservation and tumor control. We present the results of penile SCC treated with HDR brachytherapy either interstitially or via a surface mold.

Methods And Materials: Between November 2009 and April 2019, seven patients (2 T1a and 5 T2) were treated with interstitial HDR and 8 (1 Tis, six T1a, and one T1b) with surface mold.

HDR Prostate Brachytherapy.

Brachytherapy has become an essential pillar in all-stages of localized prostate cancer, where dose escalation has been demonstrated to improve outcome. HDR brachytherapy has evolved over the decades to be administered in 1-2 fractions. As either monotherapy or in combination with external beam, it offers many advantages over other treatment alternatives.